Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,461 matching trials from the live ClinicalTrials.gov search.
Conditions
Obesity & Overweight
Interventions
Healthy Eating for My Infant (HEMI)
Behavioral
Lead sponsor
University of Cincinnati
Other
Eligibility
2 Months to 21 Months
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Lung Cancer
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Conditions
Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
exemestane, adjuvant therapy, aromatase inhibition, conventional surgery, endocrine therapy, hormone therapy, neoadjuvant therapy, surgery
Drug · Procedure
Lead sponsor
Robert H. Lurie Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
Interventions
T-cell replete PBPC allograft, Methotrexate, Cyclosporine, G-CSF
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Cryoballoon Ablation
Device
Lead sponsor
Pentax Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Rochester, New York • Pittsburgh, Pennsylvania
Conditions
Pancreatic Cancer
Interventions
laparoscopy, ultrasound imaging
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Thymoma
Interventions
cisplatin and etoposide, Surgical Resection, Concurrent Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Valley Health System
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Ridgewood, New Jersey
Conditions
Follicular Lymphoma
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine phosphate, Prednisone, Diphenhydramine, Acetaminophen
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Paclitaxel, Positron Emission Tomography, Questionnaire Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Accepts healthy volunteers

Call-2-Health: Preventing Type II Diabetes

NCT01827826
Conditions
Diabetes Mellitus, Type 2
Interventions
Telephonic intervention to prevent Diabetes Mellitus, Type 2
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 74 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Accepts healthy volunteers

Breathe Easier II: A Dyad-based Multiple Behavior Intervention

NCT05956782
Conditions
Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity, Stress, Quality of Life
Interventions
Breathe Easier
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Conditions
Metastatic Melanoma, Metastatic Kidney Cancer
Interventions
Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide, Fludarabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Head and Neck Cancer, Dental Diseases, Osteoradionecrosis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
6
States / cities
Farmington, Connecticut • Boston, Massachusetts • Minneapolis, Minnesota + 3 more
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Lymphoma
Interventions
RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation
Biological · Procedure
Lead sponsor
Systemix
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 2 more
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL Negative, Blastic Phase Chronic Myelogenous Leukemia, Cancer Survivor, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Depression, Disseminated Neuroblastoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Fatigue, Long-term Effects Secondary to Cancer Therapy in Adults, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Psychosocial Effects of Cancer and Its Treatment, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma
Interventions
internet-based intervention, questionnaire administration, psychosocial assessment and care, assessment of therapy complications, management of therapy complications, fatigue assessment and management, counseling intervention
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Other
Eligibility
18 Years and older
Enrollment
1,337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Ductal Carcinoma In Situ
Interventions
Laboratory Biomarker Analysis, Nelipepimut-S Plus GM-CSF Vaccine, Sargramostim, Surgical Procedure
Other · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Conditions
Renal Cell Carcinoma (RCC)
Interventions
Intermittent Fasting, Continuous Energy Restriction (CER)
Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Conditions
Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome
Interventions
Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs, Lipoaspiration
Other
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Anxiety Disorder, Fatigue, Hematopoietic/Lymphoid Cancer, Pain
Interventions
therapeutic touch, quality-of-life assessment, questionnaire administration
Procedure · Other
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa